Demonstrates effective opioid overdose reversal in consumers, suggesting easier access to life-saving treatment.
On June 16, the Food and Drug Administration (FDA) approved over‐the‐counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. Consumers may directly purchase this product without a prescription in places such as pharmacies, convenience stores, and online. This action aligns with President Trump's Great American Recovery Initiative , a federal effort to address the U.S. addiction and substance use disorder crisis and coordinate the government's approach to prevention, treatment, and long‐term recovery.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: